CSL Behring is a global leader in the plasma protein biotherapeutics industry, providing plasma-derived therapies and their recombinant analogs that treat rare and serious diseases.

History

The company traces its roots back to Emil von Behring, an innovator with serum therapies who won the first Nobel Prize in Physiology or Medicine. The company changed its name from ZLB Behring as part of its alignment with its parent organization, CSL Limited, a specialty biopharmaceutical company based in Melbourne, Australia.

Products

CSL Behring manufactures and markets a range of plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic disease in newborns, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma.

Offices

The company is headquartered in King of Prussia, Pennsylvania. It has 7,000 employees in 19 countries. Major manufacturing centers are located in Bern, Switzerland, Marburg, Germany
and Kankakee, Illinois

Finances

The company's sales in their fiscal year 2005/2006 were approximately U.S.$ 1.8 billion